3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow GLPG2222: new trials by email Literature Review of GLPG2222 trials Research Report on GLPG2222
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis ABBV-576, Galicaftor, Placebo - Cystic Fibrosis (CF) | Phase 2 | Terminated | AbbVie | 48 | 2021-09-20 | 2024-07-16 |
| A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 ABBV-3067, Placebo ABBV-3067, ABBV-2222 - Cystic Fibrosis | Phase 2 | Completed | AbbVie | 78 | 2019-12-11 | 2023-06-28 |
| A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis GLPG2222 50 mg, GLPG2222 100 mg, Placebo - Cystic Fibrosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 59 | 2017-03-18 | 2018-11-16 |
| A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis GLPG2222 150 mg q.d., GLPG2222 300 mg q.d., Placebo - Cystic Fibrosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 37 | 2017-01-01 | 2017-11-21 |
Cystic Fibrosis (4)
AbbVie (2) · Lakefront Biotherapeutics NV (2)
Belgium (4) · Netherlands (3) · United Kingdom (3) · United States (3) · Australia (2) · Czechia (2) · Hungary (2) · New Zealand (2) · Serbia (2) · Slovakia (2) · Canada (1) · France (1) · Germany (1) · Ireland (1) · Poland (1)
Olivier Van Steen, MD, MBA (2)
PMID 31056441, PMID 33331662, PMID 37983082
2019 (1)